Skip to main content

Advertisement

SpringerLink
Log in

Use of nitazoxanide for gastrointestinal tract infections: Treatment of protozoan parasitic infection and beyond

  • Published:
Current Infectious Disease Reports Aims and scope Submit manuscript

Abstract

The United States Food and Drug Administration has approved the parasiticidal agent nitazoxanide for treatment of diarrhea caused by Giardia lamblia/intestinalis or Cryptosporidium parvum. This novel agent has a broad spectrum of activity against many other gastrointestinal pathogens, including bacteria, roundworms, flatworms, and flukes. Nitazoxanide is used in many areas of the world, especially in Central and South America, as a broad-spectrum parasiticidal agent in adults and children. Nitazoxanide appears to be well tolerated, has a relatively low incidence of adverse effect, and displays no significant known drug-to-drug interactions. Recently, preliminary reports indicate that nitazoxanide may be an effective treatment for Clostridium difficile-associated diarrhea as well. Future work will likely solidify and further expand the role of nitazoxanide in the treatment of a wide range of intestinal pathogens.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Rossignol JF, Cavier R: New derivative of 2-benzamino-5-nitrothiazoles. Chem Abstr 1975, 83:28216n.

    Google Scholar 

  2. White CA Jr: Nitazoxanide: a new broad spectrum antiparasitic agent. Expert Rev Anti Infect Ther 2004, 2:43–49.

    Article  PubMed  CAS  Google Scholar 

  3. Bailey JM, Erramouspe J: Nitazoxanide treatment for giardiasis and cryptosporidiosis in children. Ann Pharmacother 2004, 38:634–640. Review of nitazoxanide effects on protozoan gastrointestinal infections in children.

    Article  PubMed  CAS  Google Scholar 

  4. Fox LM, Saravolatz LD: Nitazoxanide: a new thiazolide antiparasitic agent. Clin Infect Dis 2005, 40:1173–1178. Detailed and current review of the pharmacology and clinical actions of nitazoxanide.

    Article  PubMed  CAS  Google Scholar 

  5. Ochoa TJ, White AC Jr: Nitazoxanide for treatment of intestinal parasites in children. Pediatr Infect Dis J 2005, 24:641–642. Another current pediatic review of this agent.

    Article  PubMed  Google Scholar 

  6. Megraud F, Occhialini A, Rossignol JF: Nitazoxanide, a potential drug for eradication of Helicobacter pylori with no cross-resistance to metronidazole. Antimicrob Agents Chemother 1998, 42:2836–2840.

    PubMed  CAS  Google Scholar 

  7. Guttner Y, Windsor HM, Viiala CH, et al.: Nitazoxanide in treatment of Helicobacter pylori: a clinical and in vitro study. Antimicrob Agents Chemother 2003, 47:3780–3783. This study showed no significant activity for nitazoxanide as a single agent, although there was potential for use of this medication as part of combination therapy.

    Article  PubMed  CAS  Google Scholar 

  8. Dubreuil L, Houcke I, Mouton Y, Rossignol JF: In vitro evaluation of activities of nitazoxanide and tizoxanide against anaerobes and aerobic organisms. Antimicrob Agents Chemother 1996, 40:2266–2267.

    PubMed  CAS  Google Scholar 

  9. McVay CS, Rolfe RD: In vitro and in vivo activities of nitazoxanide against Clostridium difficile. Antimicrob Agents Chemother 2000, 44:2254–2258. First evidence of potential use of this agent for C. difficile colitis, this study examined the in vitro activity of nitazoxanide as well as efficiacy in the hamster model of this infection.

    Article  PubMed  CAS  Google Scholar 

  10. Alinia, nitazoxanide [product information]. Tampa, FL: Romark Pharmaceuticals; 2004–2005.

  11. Nitazoxanide. In USP DI® Drug Information for the Healthcare Professional [electronic version]. Edited by Klasco RK. Greenwood Village, CO: Thomson Micromedex; 2005.

    Google Scholar 

  12. Nitazoxanide. In Martindale: The Complete Drug Reference. Edited by Sweetman SC. London: Pharmaceutical Press; 2005.

    Google Scholar 

  13. Drugs for parasitic infection. Med Lett Drugs Ther 2004, 46:1–12.

  14. Romark Labortories: Romark completes clinical study of Alinia in treating Clostridium difficile-associated disease [press release]. http://www.romark.com/index. php/media_center/press_releases/34.html. Accessed November 18, 2005.

  15. Romark Labortories: Romark advances development of Alinia in treating Clostridium difficile-associated disease [press release]. http://www.romark.com/index. php/media_center/press_releases/33.html. Accessed December 8, 2005.

  16. Smith HV, Corcoran GD: New drugs and treatment for cryptosporidiosis. Curr Opin Infect Dis 2004, 17:557–564. Detailed review of cryptosporidiosis as well as a summary of treatment options.

    Article  PubMed  CAS  Google Scholar 

  17. Zardi EM, Picardi A, Afeltra A: Treatment of cryptosporidiosis in immunocompromised hosts. Chemotherapy 2005, 51:193–196.

    Article  PubMed  CAS  Google Scholar 

  18. Huang DB, Chappell C, Okhuysen PC: Cryptosporidiosis in children. Semin Pediatr Infect Dis 2004, 15:253–259.

    Article  PubMed  Google Scholar 

  19. Lebwohl B, Deckelbaum RJ, Green PH: Giardiasis. Gastrointest Endosc 2003, 57:906–913.

    Article  PubMed  Google Scholar 

  20. Thompson RC, Monis PT: Variation in Giardia: implications for taxonomy and epidemiology. Adv Parasitol 2004, 58:69–137.

    Article  PubMed  CAS  Google Scholar 

  21. Caccio SM, Thompson RC, McLauchlin J, Smith HV: Unraveling Cryptosporidium and Giardia epidemiology. Trends Parasitol 2005, 21:430–437.

    Article  PubMed  CAS  Google Scholar 

  22. Ortiz JJ, Ayoub A, Gargala G, et al.: Randomized clinical study of nitazoxanide compared to metronidazole in the treatment of symptomatic giardiasis in children from Northern Peru. Aliment Pharmacol Ther 2001, 15:1409–1415. A prospective study of 110 children with giardiasis, comparing a 3-day course of nitazoxanide with a 5-day course of metronidazole.

    Article  PubMed  CAS  Google Scholar 

  23. Adagu IS, Nolder D, Warhurst DC, Rossignol JF: In vitro activity of nitazoxanide and related compounds against isolates of Giardia intestinalis, Entamoeba histolytica, and Trichomonas vaginalis. J Antimicrob Chemother 2002, 49:103–111.

    Article  PubMed  CAS  Google Scholar 

  24. Davila-Gutierrez CE, Vasquez C, Trujillo-Hernandez B, Huerta M: Nitazoxanide compared with quinfamide and mebendazole in the treatment of helminthic infections and intestinal protozoa in children. Am J Trop Med Hyg 2002, 66:251–254. This study extends the data showing clinical efficacy of nitazoxanide to intestinal helminth infections.

    PubMed  CAS  Google Scholar 

  25. Dillingham RA, Lima AA, Guerrant RL: Cryptosporidiosis: epidemiology and impact. Microbes Infect 2002, 4:1059–1066.

    Article  PubMed  Google Scholar 

  26. Chen XM, Keithly JS, Paya CV, LaRusso NF: Cryptosporidiosis. N Engl J Med 2002, 346:1723–1731.

    Article  PubMed  Google Scholar 

  27. Xiao L, Fayer R, Ryan U, Upton SJ: Cryptosporidium taxonomy: recent advances and implications for public health. Clin Microbiol Rev 2004, 17:72–97.

    Article  PubMed  Google Scholar 

  28. Rossignol JF, Ayoub A, Ayers MS: Treatment of diarrhea caused by Cryptosporidium parvum: a prospective randomized, double-blind, placebo-controlled study of nitazoxanide. J Infect Dis 2001, 184:103–106. The response rate to nitazoxanide in this study is amongst the highest reported for any agent against cryptosporidiosis.

    Article  PubMed  CAS  Google Scholar 

  29. Amadi B, Mwiya M, Musuku J, et al.: Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial. Lancet 2002, 360:1375–1380. Smaller prospective study showing efficiacyfor nitazoxanide for HIV-negative children, including possible mortality benefit (see also comments in text).

    Article  PubMed  Google Scholar 

  30. Rossignol JF, Hidalgo H, Feregrino M, et al.: A double-‘blind’ placebo-controlled study of nitazoxanide in the treatment of cryptosporidial diarrhoea in AIDS patients in Mexico. Trans R Soc Trop Med Hyg 1998, 92:663–666.

    Article  PubMed  CAS  Google Scholar 

  31. Juan JO, Lopez Chegne N, Gargala G, Favennec L: Comparative clinical studies of nitazoxanide, albendazole and praziquantel in the treatment of ascariasis, trichuriasis and hymenolepiasis in children from Peru. Trans R Soc Trop Med Hyg 2002, 96:193–196.

    Article  PubMed  Google Scholar 

  32. Diaz E, Mondragon J, Ramirez E, Bernal R: Epidemiology and control of intestinal parasites with nitazoxanide in children in Mexico. Am J Trop Med Hyg 2003, 68:384–385.

    PubMed  CAS  Google Scholar 

  33. Walker M, Rossignol JF, Torgerson P, Hemphill A: In vitro effects of nitazoxanide on Echinococcus granulosus protoscoleces and metacestodes. J Antimicrob Chemother 2004, 54:609–616.

    Article  PubMed  CAS  Google Scholar 

  34. Stettler M, Fink R, Walker M, et al.: In vitro parasiticidal effect of nitazoxanide against Echinococcus multilocularis metacestodes. Antimicrob Agents Chemother 2003, 47:467–474.

    Article  PubMed  CAS  Google Scholar 

  35. Favennec L, Jave Ortiz J, Gargala G, et al.: Double-blind, randomized, placebo-controlled study of nitazoxanide in the treatment of fascioliasis in adults and children from northern Peru. Aliment Pharmacol Ther 2003, 17:265–270.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Infectious Diseases, Department of Medicine, Case Western Reserve University School of Medicine, Case Medical Center, 1110 Euclid Avenue, 44106, Cleveland, OH, USA

    David A. Bobak MD

Authors
  1. David A. Bobak MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David A. Bobak MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bobak, D.A. Use of nitazoxanide for gastrointestinal tract infections: Treatment of protozoan parasitic infection and beyond. Curr Infect Dis Rep 8, 91–95 (2006). https://doi.org/10.1007/s11908-006-0003-y

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11908-006-0003-y

Keywords

Search

Navigation